Since active hepatitis B virus (HBV) replication is the key driver of hepatic necroinflammation
and disease progression, the treatment aim of chronic hepatitis B (CHB) is to suppress HBV …

Chronic hepatitis B virus (HBV) infection is still a major health problem worldwide. Recently,
a great number of genetic studies based on single nucleotide polymorphisms (SNPs) and …

Abstract Background Chronic hepatitis B (CHB) and fatty liver (FL) are common, natural
history data on concurrent FL and CHB (FL-CHB) are limited. This study aimed to evaluate …

Hepatitis C virus (HCV) infection is a silent killer that leads to rapid progression of liver
cirrhosis and hepatocellular carcinoma (HCC). High prevalence of HCV infection has been …

Asia has intermediate-to-high prevalence and high morbidity of hepatitis B virus (HBV)
infection. The use of guideline-recommended nucleos (t) ide analogs with high barrier to …

Background Antiviral therapy for patients with non-cirrhotic chronic hepatitis B and minimally
raised alanine aminotransferase (ALT) is controversial. We aimed to investigate the efficacy …

Objectives The aim of this study was to investigate hepatitis B virus (HBV) reactivation in
patients with rheumatoid arthritis (RA) receiving tofacitinib. Method This was a retrospective …

Hepatitis D virus (HDV) infection increases the risk of hepatocellular carcinoma (HCC) in the
natural course of chronic hepatitis B (CHB) patients. Its role in patients treated with …

Hepatitis B virus (HBV) infection and its related liver diseases are important health problems
worldwide, particularly in the Asia-Pacific region. For the past 4–5 decades, Taiwan's …

Background & Aims Oral antiviral therapy with nucleos (t) ide analogues (NAs) for chronic
hepatitis B (CHB) is well-tolerated and lifesaving, but real-world data on utilization are …